AMRS:NSD-Amyris, Inc (USD)

COMMON STOCK | Specialty Chemicals | NSD

Last Closing Price

USD 15.06

Change

0.00 (0.00)%

Market Cap

USD 4.35B

Volume

4.21M

Average Target Price

USD 24.25 (+61.02%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-18 )

Largest Industry Peers for Specialty Chemicals

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BCPC Balchem Corporation

N/A

USD3.98B 47.25 24.75
WDFC WD-40 Company

N/A

USD3.53B 47.33 35.21
IOSP Innospec Inc

N/A

USD2.55B 88.64 28.56
GEVO Gevo, Inc

N/A

USD1.25B 0.30 N/A
GPRE Green Plains Inc

N/A

USD1.16B 40.40 N/A
HWKN Hawkins, Inc

N/A

USD0.72B 19.73 10.89
LOOP Loop Industries, Inc

N/A

USD0.35B N/A N/A
NTIC Northern Technologies Internat..

N/A

USD0.13B 59.49 42.34
HDSN Hudson Technologies, Inc

N/A

USD0.08B 31.20 13.71
CNEY CN Energy Group. Inc

N/A

USD0.07B N/A 19.65

ETFs Containing AMRS

Symbol Name Weight Mer Price(Change) Market Cap
BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

N/A

USD0.05B
PYZ Invesco DWA Basic Materia.. 0.00 % 0.60 %

N/A

USD0.14B
THCX The Cannabis ETF 0.00 % 0.70 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Specialty Chemicals)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 143.69% 93% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 143.69% 93% A 98% A+
Trailing 12 Months  
Capital Gain 563.44% 92% A- 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 563.44% 92% A- 96% A
Trailing 5 Years  
Capital Gain -7.04% 27% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.04% 27% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 23.55% 85% B 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.55% 85% B 73% C
Risk Return Profile  
Volatility (Standard Deviation) 146.08% 23% F 9% F
Risk Adjusted Return 16.12% 38% F 38% F
Market Capitalization 4.35B 100% A+ 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Specialty Chemicals)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -24.76 67% D+ 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 114.16% 93% A 99% A+
Return on Assets -40.20% 20% F 8% F
Debt to Equity Ratio -14.80% 100% A+ 93% A
Technical Ratios  
Short Ratio 4.26 27% F 25% F
Short Percent 15.53% 13% F 11% F
Beta 1.24 46% F 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.